Qiangsheng Zhang

Chengdu, 610031, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Recent Advances and Perspectives of Small Molecule Modulators Targeting DOT1L.

Recent Advances and Perspectives of Small Molecule Modulators Targeting DOT1L.

Journal: Journal of medicinal chemistry

Published: February 28, 2026

An updated patent review of EZH2 inhibitors (2024-present).

An updated patent review of EZH2 inhibitors (2024-present).

Journal: Expert opinion on therapeutic patents

Published: March 21, 2025

Small molecule compounds targeting G9a/GLP: Recent advances and perspectives.

Small molecule compounds targeting G9a/GLP: Recent advances and perspectives.

Journal: European journal of medicinal chemistry

Published: January 08, 2025

Covalent inhibitors meet epigenetics: New opportunities.

Covalent inhibitors meet epigenetics: New opportunities.

Journal: European journal of medicinal chemistry

Published: June 20, 2024

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.

Journal: European journal of medicinal chemistry

Published: April 28, 2024

Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6).

Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6).

Journal: Bioorganic chemistry

Published: February 26, 2024

Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH.

Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH.

Journal: Life sciences

Published: October 15, 2023

Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer.

Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer.

Journal: European journal of medicinal chemistry

Published: August 23, 2023

Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.

Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.

Journal: European journal of medicinal chemistry

Published: April 27, 2023

A patent review of EZH2 inhibitors from 2017 and beyond.

A patent review of EZH2 inhibitors from 2017 and beyond.

Journal: Expert opinion on therapeutic patents

Published: April 25, 2023

Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment.

Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment.

Journal: Current topics in medicinal chemistry

Published: March 20, 2023

Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.

Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.

Journal: Molecular and cellular biochemistry

Published: February 24, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026